In this study, we sought to evaluate the association of HR pathway mutations, HR deficiency scores and CCNE1 and RB1 CNA with response to platinum retreatment in ovarian cancer patients in the platinum-resistant setting. This evidence concerns the gene RB1 and ovarian carcinoma.